Navigation Links
More Than 9 in 10 Primary Care Physicians Say U.S. Health Care System Should Place Greater Emphasis on Nutrition to Manage Chronic Disease
Date:6/10/2009

Survey Conducted with American Dietetic Association Shows Lack of Reimbursement for Nutrition Services Is Key Barrier

WASHINGTON, June 10 /PRNewswire-USNewswire/ -- Ninety-six percent of primary care physicians believe the nation's health care system should place more emphasis on nutrition to treat and manage chronic disease, according to a new survey released today. However, only 12 percent believe physicians currently pay significant attention to nutrition in the context of chronic disease.

"The good news is physicians know nutrition therapy can improve health outcomes," said registered dietitian Jane V. White, PhD, LDN, RD, FADA, with the Department of Family Medicine at the University of Tennessee Graduate School of Medicine, who partnered with the American Dietetic Association on the survey. "Now, it's time to move nutrition services to the forefront in prevention and management of chronic disease."

In the survey, nutrition services were defined as referral to a registered dietitian or recommendation of specific nutrition products.

"Nutrition is more than just eating a healthy diet; for patients with chronic disease nutrition acts as therapy to help them heal faster, respond better to medical care and control their disease," White said.

One of the biggest reasons cited for physicians' failure to address nutrition more frequently as part of chronic disease prevention and management is the lack of direct reimbursement for nutrition services. More than 80 percent of physicians surveyed said lack of reimbursement is either a major reason or the single biggest reason that providing nutrition services is not routine, including one-third who cited it as the biggest factor.

"Registered dietitians and doctors have long known the intrinsic value of nutrition services for their patients," said registered dietitian Martin Yadrick, MS, MBA, RD, FADA, imm
'/>"/>

SOURCE American Dietetic Association
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine news :

1. Is 4 agents decoction (Si Wu Tang) efficacious in treating primary dysmenorrhea?
2. Study finds primary care depression treatment often does not follow quality guidelines
3. Primary biliary cirrhosis more severe in African-American and Hispanic patients
4. New research may lead to earlier diagnosis and treatment of primary biliary cirrhosis in families
5. Revisions to College Cost Reduction and Access Act will create barriers to primary care
6. New Hampshire: 1st in the Nation Primary State Takes a Stand on E-Prescribing
7. Editorial says primary care system must change how it approaches dementia
8. S&P: Leverage Tops Politics as Primary Credit Concern for U.S. Health Care Companies, Says S&P
9. ENDEAVOR IV achieves primary endpoint, demonstrates similar safety profile compared to Taxus stent
10. Visual field loss primary component in risk of falls for older adults
11. Triumph-1 Trial of Viveta in Pulmonary Arterial Hypertension Meets Primary Endpoint

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/21/2009)...isions of Legislation, Continues Push for Progress...ov. 21 With the U.S. ...rdable Health Care for America Act (H.R. 3962), an...forward, Congress has taken decisive steps to fix ...RP hosted an educational forum to discuss the prov...
(Date:11/21/2009)...l apparel company launches men,s lab coats at Medi...Clemente, Calif. (PRWEB) November 21, 2009 -- Mede...today announced the launch of its men,s lab coats,...ternational trade fair for the medical industry he...s men,s collection with three varying lab coat sty...
(Date:11/21/2009)...Group merges their practice with that of E. Steven... (PRWEB) November 21, 2009 -- The New Hav...ibson, Dr. Dean Cloutier, Dr. John Plachtyna and D...practice with that of esteemed colleague Dr. E. St...ed to retire from dentistry in order to concentrat...
(Date:11/20/2009)...ire-FirstCall/ - NUCRYST Pharmaceuticals Corp. ann...s will be held on Monday, December 21, 2009. The p...wo special resolutions. The first special resoluti...substantially all of the assets of NUCRYST, substa...chase agreement dated November 10, 2009 among the ...
(Date:11/20/2009)...re/ -- Following a recall by Unilever The Stop &am...d,s Country Crock ® Side Dishes DELUXE Chedda...ide Dishes DELUXE Four Cheese Pasta due to an unde... dates and UPCs are affected: ,, Shedd,s Count...i Rice 21 oz, UPC 027400218316, Best By NOV 29 09 ...
Breaking Medicine News(10 mins):Health News:AARP Hosts Rep. Bill Foster In Health Care Reform Forum 2Health News:Medelita Introduces Men's Lab Coat Collection 2Health News:Medelita Introduces Men's Lab Coat Collection 3Health News:New Haven Dental Group Expands Their Vision 2Health News:NUCRYST Announces Special Meeting of Shareholders 2Health News:NUCRYST Announces Special Meeting of Shareholders 3Health News:Stop & Shop Alerts Customers to Voluntary Recall by Unilever 2
... facility on Sand Canyon Avenue , ...- Hoag Memorial Hospital Presbyterian has reached ...tate Investment Trust headquartered in Long Beach,...Tenet Healthcare Corporation (NYSE: THC) as Irvine...
... today announced a revised date to report its 2008.... ev3 will now report its 2008 second quarter,and ... 2008, after regular,market trading hours., The c...w its second quarter operating results and future,...
... Experience it at http://SutterHealth.org/an... an e-patient?,Studies show that 80 percent of Ame...ion. Thanks to Web 2.0, e-patients now have even m...alreport ,and you,ll see one of the ways Sutter He...
...ent-resistant, study shows , , THURSDAY, J...e evidence that a new AIDS drug brings significant...ents. , The drug, known as raltegravir (Isentress)...y 24 issue of the New England Journal of Medicine...
...lth and,safety services company, today announced t...les to Living Abroad.com and its multi-national em...-filled online guides to trusted,medical care in h...e assigned abroad on topics such as health service...
...Frank,Ervolino, ND, investigated a product that cl...isks associated with stimulants. He reports that,A...tural product from Zurich,Pharmaceuticals, makes n...DC estimates that greater than 30% of adults are o...
Other Medicine News:Health News:Hoag Hospital Announces Agreement to Open Irvine Campus 2Health News:ev3 Inc. Announces Revised Date for 2008 Second Quarter Financial Results and Conference Call 2Health News:Internet Video Revolution - Sutter Health Harnesses Power of Web 2.0 to Inform Customers 2Health News:Internet Video Revolution - Sutter Health Harnesses Power of Web 2.0 to Inform Customers 3Health News:Internet Video Revolution - Sutter Health Harnesses Power of Web 2.0 to Inform Customers 4Health News:Drug Holds Promise Against AIDS 2Health News:HTH Worldwide to Provide International Health Guide to Living Abroad.com 2Health News:New Natural Product from Zurich Pharmaceuticals Downs Appetite 2
(Date:11/20/2009).... 20 Cyberonics, Inc. (N...sident and Chief Executive Officer, and Greg Brown...st Annual Piper Jaffray Health Care Conference in ...M EST. The conference session and webcast will be.... Piper Jaffray will host a webcast of the presen...
(Date:11/20/2009)...J., Nov. 20 Soligenix, I...ompany), formerly known as DOR BioPharma, Inc., a ...that it has formed a consortium to develop thermos...pidly acting vaccines. Soligenix received a $9.4 m...y and Infectious Diseases (NIAID), a division of t...
(Date:11/19/2009)...o., Nov. 19 In a series ...ience, Heska Corporation (Nasdaq: HSKA ) ("Heska"...ts new and improved website. The upgraded site is...and programming to align the site with the company..., (Logo: http://www.newscom.com/cgi-bin/prnh/200...
Breaking Medicine Technology:Cyberonics to Present at 21st Annual Piper Jaffray Health Care Conference 2Soligenix Forms Consortium to Develop Thermostable Technology to Advance RiVax(TM) and Other Rapidly Acting Vaccines 2Soligenix Forms Consortium to Develop Thermostable Technology to Advance RiVax(TM) and Other Rapidly Acting Vaccines 3Soligenix Forms Consortium to Develop Thermostable Technology to Advance RiVax(TM) and Other Rapidly Acting Vaccines 4Soligenix Forms Consortium to Develop Thermostable Technology to Advance RiVax(TM) and Other Rapidly Acting Vaccines 5Soligenix Forms Consortium to Develop Thermostable Technology to Advance RiVax(TM) and Other Rapidly Acting Vaccines 6Heska Announces Launch of New Website 2Heska Announces Launch of New Website 3Sigma Aldrich 28Nasdaq 3ASIAL 29 Reports Q2 2009 Diluted EPS of 240 68 3B YTD Diluted EPS up 1 5 25 to 241 36 Full Year 2009 Guidance Reaffirmed 13165 1Sigma Aldrich 28Nasdaq 3ASIAL 29 Reports Q2 2009 Diluted EPS of 240 68 3B YTD Diluted EPS up 1 5 25 to 241 36 Full Year 2009 Guidance Reaffirmed 13165 2Sigma Aldrich 28Nasdaq 3ASIAL 29 Reports Q2 2009 Diluted EPS of 240 68 3B YTD Diluted EPS up 1 5 25 to 241 36 Full Year 2009 Guidance Reaffirmed 13165 3Sigma Aldrich 28Nasdaq 3ASIAL 29 Reports Q2 2009 Diluted EPS of 240 68 3B YTD Diluted EPS up 1 5 25 to 241 36 Full Year 2009 Guidance Reaffirmed 13165 4Sigma Aldrich 28Nasdaq 3ASIAL 29 Reports Q2 2009 Diluted EPS of 240 68 3B YTD Diluted EPS up 1 5 25 to 241 36 Full Year 2009 Guidance Reaffirmed 13165 5Sigma Aldrich 28Nasdaq 3ASIAL 29 Reports Q2 2009 Diluted EPS of 240 68 3B YTD Diluted EPS up 1 5 25 to 241 36 Full Year 2009 Guidance Reaffirmed 13165 6Sigma Aldrich 28Nasdaq 3ASIAL 29 Reports Q2 2009 Diluted EPS of 240 68 3B YTD Diluted EPS up 1 5 25 to 241 36 Full Year 2009 Guidance Reaffirmed 13165 7Sigma Aldrich 28Nasdaq 3ASIAL 29 Reports Q2 2009 Diluted EPS of 240 68 3B YTD Diluted EPS up 1 5 25 to 241 36 Full Year 2009 Guidance Reaffirmed 13165 8Sigma Aldrich 28Nasdaq 3ASIAL 29 Reports Q2 2009 Diluted EPS of 240 68 3B YTD Diluted EPS up 1 5 25 to 241 36 Full Year 2009 Guidance Reaffirmed 13165 9Sigma Aldrich 28Nasdaq 3ASIAL 29 Reports Q2 2009 Diluted EPS of 240 68 3B YTD Diluted EPS up 1 5 25 to 241 36 Full Year 2009 Guidance Reaffirmed 13165 10Sigma Aldrich 28Nasdaq 3ASIAL 29 Reports Q2 2009 Diluted EPS of 240 68 3B YTD Diluted EPS up 1 5 25 to 241 36 Full Year 2009 Guidance Reaffirmed 13165 11Sigma Aldrich 28Nasdaq 3ASIAL 29 Reports Q2 2009 Diluted EPS of 240 68 3B YTD Diluted EPS up 1 5 25 to 241 36 Full Year 2009 Guidance Reaffirmed 13165 12Sigma Aldrich 28Nasdaq 3ASIAL 29 Reports Q2 2009 Diluted EPS of 240 68 3B YTD Diluted EPS up 1 5 25 to 241 36 Full Year 2009 Guidance Reaffirmed 13165 13Sigma Aldrich 28Nasdaq 3ASIAL 29 Reports Q2 2009 Diluted EPS of 240 68 3B YTD Diluted EPS up 1 5 25 to 241 36 Full Year 2009 Guidance Reaffirmed 13165 14Sigma Aldrich 28Nasdaq 3ASIAL 29 Reports Q2 2009 Diluted EPS of 240 68 3B YTD Diluted EPS up 1 5 25 to 241 36 Full Year 2009 Guidance Reaffirmed 13165 15Sigma Aldrich 28Nasdaq 3ASIAL 29 Reports Q2 2009 Diluted EPS of 240 68 3B YTD Diluted EPS up 1 5 25 to 241 36 Full Year 2009 Guidance Reaffirmed 13165 16Sigma Aldrich 28Nasdaq 3ASIAL 29 Reports Q2 2009 Diluted EPS of 240 68 3B YTD Diluted EPS up 1 5 25 to 241 36 Full Year 2009 Guidance Reaffirmed 13165 17Narconon Trois Rivieres Cites Hillbilly Heroin as Canadian Drug Addiction Crisis 52510 1Narconon Trois Rivieres Cites Hillbilly Heroin as Canadian Drug Addiction Crisis 52510 2Patterson Companies Expands Deployment of MicroStrategy for Enhanced Reporting and Analytics 52508 1Patterson Companies Expands Deployment of MicroStrategy for Enhanced Reporting and Analytics 52508 2Patterson Companies Expands Deployment of MicroStrategy for Enhanced Reporting and Analytics 52508 3
...e SNS-595 to Next Stage of Phase 2 Trial Achieved,...OR RELEASE AT 3:30 P.M. EDT, TODAY/ -- Sunesis Pha...age biopharmaceutical company developing novel,ant...liminary results from,the first stage of the compa...oduct candidate, SNS-595, in platinum-resistant ov...
...WASHINGTON, Oct. 23 Boston,Scientific Corporation...,results from its CABERNET and BEACH carotid arter...the effectiveness of stenting with embolic,protect...ectomy (CEA), the,surgical treatment for carotid a...esults were presented by L. Nelson Hopkins, M.D., ...
Other Medicine Technology:Sunesis Pharmaceuticals Reports Preliminary SNS-595 Activity in Ovarian Cancer Clinical Trial at AACR-NCI-EORTC International Conference 2Sunesis Pharmaceuticals Reports Preliminary SNS-595 Activity in Ovarian Cancer Clinical Trial at AACR-NCI-EORTC International Conference 3Sunesis Pharmaceuticals Reports Preliminary SNS-595 Activity in Ovarian Cancer Clinical Trial at AACR-NCI-EORTC International Conference 4Sunesis Pharmaceuticals Reports Preliminary SNS-595 Activity in Ovarian Cancer Clinical Trial at AACR-NCI-EORTC International Conference 5Boston Scientific Carotid Artery Stenting Trials Produce Positive Three-Year Results 2Boston Scientific Carotid Artery Stenting Trials Produce Positive Three-Year Results 3Boston Scientific Carotid Artery Stenting Trials Produce Positive Three-Year Results 4Boston Scientific Carotid Artery Stenting Trials Produce Positive Three-Year Results 5
Bledsoe Extender Knee Brace
Bledsoe Post-Op Knee Brace
Bledsoe Basic Knee Brace
Extensor™ Patellar Knee Support with Lateral Strap
Medicine Products: